72P Cemiplimab monotherapy for first-line advanced NSCLC patients with PD-L1 expression ≥50%: 6-y outcomes of EMPOWER-Lung 1
Gogishvili M., Kilickap S., Cicin I. et al
ESMO Open Science for Optimal Cancer Care, 2026
DOI: 10.1016/j.esmoop.2026.106379
Gogishvili M., Kilickap S., Cicin I. et al
ESMO Open Science for Optimal Cancer Care, 2026
DOI: 10.1016/j.esmoop.2026.106379